Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Looks really good.

<< Previous

Bullboard Posts

Next >>

Comment by JohnnyYegon May 21, 2021 9:12pm

267 Views

Post# 33253051

RE:Looks really good.

To put that in perspective - you would like to see $9+ per share. That is a market capitalization of a it $520 million. I always make reference to Gilead buying Forty Seven for $4.7 billion. Forty Seven had one product in Phase 1B when they were bought out. Just sayin...

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec